Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?

Aim: The clinical symptoms and laboratory markers of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) can be very similar, so making a differential diagnosis between these two diseases is often difficult. Serological parameters to be used in differential diagnosis can guide the clinician. This study aimed to investigate the usability of 14-3-3? (eta) protein as a biomarker in the differential diagnosis of PsA and RA, and the relationships between eta protein and disease activity scores and joint erosions in PsA and RA. Methods: 54 PsA patients, 53 RA patients, and 56 healthy individuals were included in this study. The ELISA (Enzyme-Linked ImunoSorbent Assay) kit was used as a quantitative sandwich enzyme immunoassay technique to detect human eta protein levels. Receiver-operating Characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of the eta protein. Results: Eta protein levels were found to be significantly higher in the RA group than in the PsA [B:-0.341, OR (95% CI): 0.711 (0.556-0.909), p: 0.007] and control [B:-0.225, OR (95% CI): 0.798 (0.641-0.995), p: 0.045] groups. Eta protein median values were significantly higher in patients with joint erosion than in those without [?= 0.151, OR (95% CI): 1.163 (1.003-1.349), p: 0.046]. Conclusion: Eta protein levels are higher in the serum of RA patients than PsA and are associated with joint erosion. Eta protein may be a potential biomarker in the differential diagnosis of RA and PsA. It may represent a possible therapeutic step in the pathophysiological pathways in the development of joint erosion. © 2024 Bentham Science Publishers.